Novartis has committed an upfront $200 million to Arrowhead Pharmaceuticals for exclusive rights to develop ARO-SNCA, a preclinical RNA interference therapy targeting alpha-synuclein, implicated in Parkinson's disease and synucleinopathies. This deal could yield over $2 billion in milestones and royalties. Arrowhead’s TRiM platform simplifies CNS drug delivery via subcutaneous dosing, avoiding invasive administration methods. The collaboration reflects Novartis’s strategic focus on innovative approaches to neurodegeneration, with Novartis handling late-stage clinical development and commercialization while Arrowhead leads preclinical research. This partnership underscores growing industry interest in RNAi modalities for challenging neurodegenerative conditions.